BLOOD PRODUCT

The Defense Health Agency is procuring blood products on a sole-source basis under the Simplified Acquisition Threshold to meet urgent contingency operational needs, with the procurement assigned to Blood Centers of America due to its exclusive capability to supply Leukoreduced, Type O Whole Blood with a 35-day shelf life and liquid plasma with a 40-day shelf life—capabilities unmatched by other suppliers, including the American Red Cross. This action is part of the Contingency Blood Procurement Program and is justified under FAR Part 12.102 and 12.201-1 as a commercial purchase requiring immediate delivery by June 16, 2026, with contract execution expected by June 10, 2026. The place of performance is administratively tied to Falls Church, Virginia, while the product Origin is the contractor’s facility in West Warwick, Rhode Island, with final acceptance to occur at overseas military locations where the blood products are deployed. No formal contract clauses, evaluation factors, line-item pricing, or packaging specifications are included in the documentation; instead, the procurement relies on narrative certifications from DHA officials attesting to cost reasonableness and technical necessity, with pricing aligned to the contractor’s current price list. The procurement is funded through Operations & Maintenance appropriations under agency code HT0011, and while the contract value remains unspecified due to missing CLIN data, the urgency and sole-source nature eliminate competitive processes and standard inspection or delivery protocols from the solicitation. Contact for the procurement is Nakaura C Yusuf at the DHA Professional Services Contracting Division, with no designated Contracting Officer’s Representative identified and no formal representations or certifications provided by the offeror beyond the government’s internal justification.